NasdaqGS - Nasdaq Real Time Price ? USD Caribou Biosciences, Inc. (CRBU) Follow Compare 1.9800 +0.0100 (+0.51%) At close: October 22 at 4:00 PM EDT 1.9500 -0.03 (-1.52%) After hours: October 22 at 5:50 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024 BERKELEY, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an abstract has been accepted for a poster presentation at the American College of Rheumatology (ACR) Convergence 2024, which will be held November 14-19, 2024 in Washington, DC. The poster will highlight the preclinical data and key elements of the clinical trial design that supported the investigational new drug GlobeNewswire ? 27 days ago CRBU +0.51% With 60% ownership, Caribou Biosciences, Inc. (NASDAQ:CRBU) boasts of strong institutional backing Key Insights Given the large stake in the stock by institutions, Caribou Biosciences' stock price might be vulnerable... Simply Wall St. ? last month CRBU +0.51% Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML -- Fast Track designation is designed to expedite clinical development and regulatory review timelines -- -- Additional FDA designation for CB-010 following earlier RMAT and Fast Track designations in B-NHL -- -- CB-010 GALLOP Phase 1 trial in patients with LN and ERL is on track to initiate by YE 2024 -- -- CB-012 AMpLify Phase 1 trial advancing in dose escalation -- BERKELEY, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR ge GlobeNewswire ? last month CRBU +0.51% Caribou Biosciences to Participate in Upcoming Investor Conferences BERKELEY, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced company leadership will participate in the following event and investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference, New York, NYSeptember 4, 2024 2024 Wells Fargo Healthcare Conference, Boston, MASeptember 5, 2024 During these conferences, Caribou leadership will conduct one-on-one meeting GlobeNewswire ? last month CRBU +0.51% Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer -- Highly-experienced hematologist and oncologist with proven track record successfully driving global clinical development of CAR-T cell therapies -- BERKELEY, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Tina Albertson, MD, PhD, as chief medical officer. Dr. Albertson brings 15 years of experience leading clinical drug development of cellular thera GlobeNewswire ? 2 months ago CRBU +0.51% Caribou Biosciences Second Quarter 2024 Earnings: Beats Expectations Caribou Biosciences ( NASDAQ:CRBU ) Second Quarter 2024 Results Key Financial Results Revenue: US$3.46m (down 7.7% from... Simply Wall St. ? 2 months ago CRBU +0.51% Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Tops Revenue Estimates Caribou Biosciences (CRBU) delivered earnings and revenue surprises of 6.67% and 4.56%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 2 months ago CRBU +0.51% Caribou Biosciences Reports Second Quarter 2024 Financial Results and?Provides Business Update -- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; clinical data reports planned for 2024 and H1 2025 -- -- Enrolling 2L LBCL and prior CD19 relapsed LBCL patients based on CB-010 ANTLER Phase 1 data presented at 2024 ASCO Annual Meeting; data to be presented H1 2025 -- -- $311.8 million in cash, cash equivalents, and marketable securities expected to fund the current operating plan into H2 2026; cash runway extension of at least 6 months versus prior GlobeNewswire ? 2 months ago CRBU +0.51% Caribou Biosciences, Inc. (CRBU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Caribou Biosciences (CRBU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Zacks ? 2 months ago CRBU +0.51% Caribou lays off staff; Roche walks away from Relay Caribou is slashing its workforce by 12%. Elsewhere, a CDMO is investing in GLP-1 drug demand and Beam’s CFO is returning to J.P. Morgan. BioPharma Dive ? 3 months ago ROG.SW CLDX BEAM -1.77% Is Caribou Biosciences (NASDAQ:CRBU) In A Good Position To Deliver On Growth Plans? Just because a business does not make any money, does not mean that the stock will go down. For example, although... Simply Wall St. ? 3 months ago CRBU +0.51% Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board -- Dr. Laufer is an immunologist advancing the scientific understanding and treatment of autoimmune diseases -- BERKELEY, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Terri Laufer, MD, to its scientific advisory board. Dr. Laufer is a leading rheumatologist known for her extensive research into immune cell regulation and dysfunction that leads to aut GlobeNewswire ? 3 months ago CRBU +0.51% Top Midday Decliners Top Midday Decliners PREMIUM MT Newswires ? 4 months ago ADRTW CRBU +0.51% Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting -- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER patients with partial HLA matching (≥4 alleles) -- -- Plan to enroll ~20 additional 2L LBCL patients in ANTLER to confirm that partial HLA matching improves patient outcomes; initial data expected in H1 2025 -- -- Caribou expects to initiate a pivotal trial for CB-010 in H2 2025, upon confirmation o GlobeNewswire ? 4 months ago CRBU +0.51% Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences BERKELEY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following event and investor conferences: ? Caribou’s webcast of KOL discussion from 2024 American Society of Clinical Oncology (ASCO) Annual MeetingJune 2, 2024, CB-010 ANTLER Phase 1 clinical trial data in r/r B-NHL to be shared in a press release at 6:00 pm CDT followed by a liv GlobeNewswire ? 4 months ago CRBU +0.51% 3 Underappreciated Stocks That Could 10x in 10 Years Like achieving a hole-in-one, holding a tenbagger is one of the best results any investor could wish for. A term popularized by legendary investor Peter Lynch, these stocks are innovators with the potential to grow exponentially. Indeed, 10x stocks are market disrupters and innovators. And they create products people love. Today, I’m on the hunt for three potential 10x stocks to result in a home run. To come up with the list, I screened for the following criteria: Small-mid cap stocks ($300 mill InvestorPlace ? 5 months ago VERV +2.52% CRBU +0.51% RVNC Caribou Biosciences, Inc. (NASDAQ:CRBU) Analysts Are Cutting Their Estimates: Here's What You Need To Know Caribou Biosciences, Inc. ( NASDAQ:CRBU ) shareholders are probably feeling a little disappointed, since its shares... Simply Wall St. ? 5 months ago CRBU +0.51% Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates Caribou Biosciences (CRBU) delivered earnings and revenue surprises of -17.95% and 19.03%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 5 months ago CRBU +0.51% Caribou Biosciences Reports First Quarter 2024 Financial Results and?Provides Business Update -- Advancing CB-010 ANTLER Phase 1 trial in 2L LBCL; initial dose expansion data to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting -- -- Expanding into autoimmune diseases with IND cleared for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; multiple milestones ahead -- -- $345.9 million in cash, cash GlobeNewswire ? 5 months ago CRBU +0.51% Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting BERKELEY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts have been accepted for poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31-June 4, 2024 in Chicago, Illinois. The ANTLER poster will provide initial dose expansion data. Details of the poster presentation are as follows: Title: A CRI GlobeNewswire ? 5 months ago CRBU +0.51% Performance Overview Trailing total returns as of 10/22/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return CRBU S&P 500 YTD -65.45% +22.67% 1-Year -49.36% +38.52% 3-Year -90.19% +28.60%
